前列腺癌患者的二次癌症 通过先进的外部光束辐射疗法治疗的前列腺癌患者
Sarah E Kulkarni1, Sagar A Patel2, Yuxian Sun1
1Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
International journal of particle therapy
|September 19, 2024
概括
与强度调节放射治疗 (IMRT) 相比,前列腺癌患者的质子束疗法 (PBT) 和立体体辐射疗法 (SBRT) 显示较低的第二次原发性癌症风险. 这些先进的辐射技术提供了更安全的治疗选择.
科学领域:
- 在瘤学瘤学.
- 辐射瘤学 辐射瘤学
- 癌症流行病学 癌症流行病学
背景情况:
- 外部光束辐射疗法与前列腺癌 (PCa) 患者的第二原发性癌症 (SPC) 风险增加有关.
- 像质子束疗法 (PBT) 和立体体辐射疗法 (SBRT) 与强度调节辐射疗法 (IMRT) 等先进辐射方式的SPC风险的比较仍然不清楚.
研究的目的:
- 评估与IMRT相比,接受PBT和SBRT治疗的PCa患者中SPC的相对概率.
- 评估较新的辐射技术在降低二次癌症风险方面的安全性和有效性.
主要方法:
- 利用国家癌症数据库 (NCDB) 确定在2004年至2018年期间诊断的N0M0个PCa病例.
- 在接受治疗意图PBT,SBRT和IMRT的患者中比较SPC概率.
- 在调整分析中使用多变量逻辑回归和治疗加权的逆概率 (IPTW).
主要成果:
- 总共有133,898名患者进行了分析 (PBT: 2.6%,IMRT: 90.5%,SBRT: 6.9%).
- 与IMRT相比,PBT和SBRT与SPC风险显著降低相关 (PBT的aOR:0.49,SBRT的aOR:0.57;P<.001).与IBRT相比,PBT和SBRT的风险显著降低 (PBT的aOR:0.49,SBRT的aOR:0.57;P<.001).
- IPTW的分析证实了PBT和SBRT的SPC风险降低.
结论:
- 在一个大型的国家队列中,PBT和SBRT在SPC风险方面表现出类似的结果.
- 与IMRT相比,PBT和SBRT都与降低SPC风险有关,作为前列腺癌的第一线治疗.
- 这些发现支持使用PBT和SBRT来潜在地改善前列腺癌患者的长期结果.
更多相关视频
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.0K
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.4K
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Disorders of the Male Reproductive System
354
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
354
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Cancer Survival Analysis
331
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
331
